Market Newsdesk

TORONTO, Dec. 10, 2020 (GLOBE NEWSWIRE) — Today Abell Pest Control announced that it is giving every Abell employee in North America a $500 gift, taxes paid, to incentivize spending in their communities in support of local businesses this holiday season. In addition to that, Abell Branches in both Canada and the U.S. will be contributing another $500 per branch to local food banks to help meet the needs of individuals experiencing food insecurity.

“Here at Abell, we hear every day from our employees and our customers how COVID-19 has impacted their businesses, the community, and their lives,” said John Abell, President, Abell Pest Control. “We wanted to do something to thank and support not only our employees but our neighbourhoods. This is our way of making the season a little brighter for everyone.”

Abell employees in Branches across North America, will receive cheques by special delivery this week. The company is encouraging people to pay it forward by spending the money in local businesses in their communities this holiday season. “Communities are the cornerstone of our company and we hope to inspire people to support and do what they can to help businesses weather the pandemic storm,” added Abell.

Food banks across North America have been severely impacted by the pandemic this year and hundreds of thousands of people need emergency food support. Abell is proud to announce that Branches in Canada and the United States will donate $500 to food banks in their local communities to help those in need.

“We are happy to do what we can to help food banks who are experiencing a drop in donations and an increase in use as a result of COVID-19,” said Abell. “We hope this donation shows our commitment to the communities where we live, work, and play.”

Abell Pest Control is a North American leader in pest control, hygiene, and disinfection services offering businesses and homeowners effective, safe, and dependable solutions since 1924. To learn more about Abell visit: www.abellpestcontrol.com

For more information contact:
Eliana Pasquariello, Abell Pest Control, [email protected]

CellBounce
3G-
t
o-4G
radio
c
onversion
s
olution
c
ertified
f
or
u
se on AT&T
n
etwork

ADT
to
deploy c
ustomer
-installable conversion solution for 3G
s
unset
expected to minimize the
need for in-person,
required
upgrades

BOCA RATON, Fla., Dec. 10, 2020 (GLOBE NEWSWIRE) — ADT (NYSE: ADT) has closed its previously announced acquisition of technology company CellBounce following thorough testing of its proprietary 3G-to-4G radio conversion technology, which is now certified for use on AT&T’s 4G cellular network. The user-installable device is expected to reduce the need for technicians to perform the required upgrade in many customer homes before the 3G network sunset. The device also will be made commercially available to third parties, allowing the larger security industry to benefit from this cost-saving radio conversion technology.

“We are very pleased the teams at ADT, AT&T, and CellBounce successfully created and certified an innovative solution to an industry-wide challenge that alleviates the need to send technicians into customers’ homes,” said Jim DeVries, President and CEO of ADT. “The CellBounce solution is expected to be a key part of our customer upgrade strategy in 2021.”

“By minimizing the need for in-home technician visits, CellBounce will help make the migration from 3G as seamless as possible,” said Robert Boyanovsky, vice president of Mobility and Internet of Things, AT&T.

First announced earlier this year, CellBounce is a plug-and-play conversion technology designed to solve one of the home security industry’s biggest logistical and financial challenges in the next year and a half. Many home security customers with 3G radios in their security panels can receive and utilize the CellBounce device, similar to a smart plug, by simply plugging it in to a power outlet near their security panel to enable continued cellular connection well beyond the 3G sunset.

The technology operates by converting 3G signals to communicate on AT&T’s 4G network, and the device can be plugged into a standard home power outlet. The CellBounce unit is equipped with a UL compliant battery back-up, that provides continuity for up to 24 hours in the case of power failure.

ADT worked closely with the CellBounce engineering team for over a year to ensure the solution works seamlessly. CellBounce has been tested and certified to support ADT customers and has received ETL and FCC certifications. ADT plans to deploy the device to ADT customers and offer it for sale to other security providers in early 2021. In addition, ADT is working on solutions to leverage the technology in other industries impacted by the 3G sunset.

FORWARD-LOOKING STATEMENTS

ADT has made statements in this press release and other reports, filings, and other public written and verbal announcements that are forward-looking and therefore subject to risks and uncertainties. All statements, other than statements of historical fact, included in this press release are, or could be, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are made in reliance on the safe harbor protections provided thereunder. These forward-looking statements relate to, among other things, our successful deployment of a commercially viable CellBounce solution; industry and consumer acceptance of such solution; cost effectiveness of such solution; successful integration of our acquisition of CellBounce; successful post acquisition implementation of the CellBounce solution; and other matters. Any forward-looking statement made in this press release speaks only as of the date on which it is made. ADT undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. Forward-looking statements can be identified by various words such as “expects,” “intends,” “will,” “anticipates,” “believes,” “confident,” “continue,” “propose,” “seeks,” “could,” “may,” “should,” “estimates,” “forecasts,” “might,” “goals,” “objectives,” “targets,” “planned,” “projects,” and similar expressions. These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. ADT cautions that these statements are subject to risks and uncertainties, many of which are outside of ADT’s control, and could cause future events or results to be materially different from those stated or implied in this press release, including among others, risk factors that are described in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission, including the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained therein.

ABOUT ADT

ADT is a leading provider of security, automation, and smart home solutions serving consumer and business customers through more than 200 locations, 9 monitoring centers, and the largest network of security professionals in the United States. The company offers many ways to help protect customers by delivering lifestyle-driven solutions via professionally installed, do-it-yourself, mobile, and digital-based offerings for residential, small business, and larger commercial customers. For more information, please visit www.adt.com or follow on Twitter, LinkedIn, Facebook, and Instagram.

Media Contact:

Paul Wiseman
[email protected]
561-356-6388

• €1.18 billion acquisition provides for significant returns to PPF Group as NBE’s largest shareholder

• SOTIO, a clinical stage immuno-oncology company, and a member of PPF Group, continues development of two ADC products under the collaboration with NBE

PRAGUE, Czech Republic, Dec. 10, 2020 (GLOBE NEWSWIRE) — PPF Group, an international investment group, today announced the signing of a binding agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim. NBE-Therapeutics is using its proprietary iADC™ platform to develop potential best-in-class antibody-drug conjugate (ADC) therapies for the treatment of solid tumors. The lead program NBE-002, an iADC targeting ROR1, entered the Phase 1 clinical testing in 2020.

The transaction is worth up to €1.18 billion, and is comprised of an upfront payment to NBE’s shareholders as well as contingent clinical and regulatory milestones. Transaction is subject to customary closing conditions.

PPF Group initially invested into NBE four years ago, and was NBE’s largest shareholder at the time of the acquisition.

NBE-Therapeutics, as part of Boehringer, will remain at its campus in Basel, Switzerland and will continue to support the existing partnership with PPF-owned SOTIO on SOTIO’s two preclinical-stage ADC programs, SO-N102 and SO-N107. SOTIO is focused on developing clinical stage immuno-oncology therapeutics and directing the biotechnology investments of PPF.

“We’d like congratulate the NBE team on this major achievement and express our sincere gratitude to everybody who supported this journey over the last years,” said Jens Hennecke, Ph.D., chief business officer of SOTIO and a member of the board of directors of NBE. “From the beginning, we have been excited about the prospect of NBE’s iADC platform. This landmark acquisition, one of the largest of its kind in Europe, provides an important validation for our approach and points to the significant value of our two ADC candidates, SO-N102 and SO-N107. We look forward to continuing our partnership with NBE-Therapeutics to advance SO-N102 into the clinics by the end of 2021 and continue the preclinical activities for SO-N107.”  

Ladislav Bartoníček, shareholder of PPF Group, added, “We are excited for the future of NBE-Therapeutics as part of Boehringer Ingelheim. Boehringer will now use its expertise and commitment to oncology research to realize the potential of the iADC platform to create best-in-class ADC therapies for the benefit of patients. This acquisition validates our business model of investing into companies with potentially game-changing platforms and products.”  

Notes for Editors
PPF Group invests in multiple market segments including financial services, telecommunications, media, biotechnology, real estate and mechanical engineering. PPF Group’s growth rests on the development of traditional and new industries, the building of modern infrastructure, the digital economy and linking up Czech talent and capabilities with global opportunities. PPF Group’s reach spans from Europe to North America and across Asia. The Group owns assets worth EUR 44 billion and employs 98,000 people globally (as at 30 June 2020). PPF pays income taxes in each of 25 countries in which it operates and generates profit.

www.ppf.eu

www.twitter.com/ppfgroup

www.linkedin.com/company/ppf

SOTIO

is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group. For more information, please visit the company’s website at sotio.com. SOTIO is a registered trademark of SOTIO a.s. in selected countries.

WESTLAKE VILLAGE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) — MannKind
Corporation
(N
asdaq
:
MNKD) today announced that James S. Shannon, M.D., MRCP (UK) has been named the new Chairman of the Board of Directors effective December 9, 2020. Kent Kresa, the former Chairman of the Board, will continue to serve on MannKind’s Board of Directors and as Chair of the Compensation Committee of the Board.

“Kent has done an incredible job leading the Board – as Chairman for the last four years and as Lead Independent Director for an additional five years prior to that,” said James Shannon. “As Al Mann’s successor, Kent helped continue Al’s mission of addressing the unmet needs of patients with diabetes and other serious illnesses. Since joining the Board in 2004, Kent has contributed significantly to the Company’s progress and he will certainly continue to do so. We are grateful for his leadership and we look forward to continuing to benefit from his experience.”

Dr. Shannon served on the Board from February 2010 until April 2012 then rejoined the Board in May 2015. Dr. Shannon is a recognized pharmaceutical industry leader with more than 20 years of experience in senior leadership positions. He served as the Chief Medical Officer for GlaxoSmithKline from 2012 -2015 and prior to this, served as Global Head of Pharma Development for Novartis AG based in Basel, Switzerland. Dr. Shannon is trained in Medicine and Cardiology and received his undergraduate and postgraduate degrees at Queen’s University of Belfast and is a Member of the Royal College of Physicians (UK). He currently serves on the boards of several companies including Horizon Therapeutics, Kyowa Kirin, Immodulon Therapeutics Limited, ProQR Therapeutics NV, and myTomorrows.

“I would like to thank Kent for our partnership during my time with MannKind,” said Michael Castagna, Chief Executive Officer of MannKind. “He has been a great mentor, for which I will be forever thankful. Having James as Kent’s successor speaks to the caliber of our Board. James’ keen insight and leadership experience in the pharmaceutical industry will be invaluable as we continue to advance the pipeline and focus on developing innovative medicines for both endocrinology and orphan lung diseases.”

About Mann
Kind
Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind’s filings with the SEC. For a discussion of these and other factors, please refer to MannKind’s annual report on Form 10-K for the year ended December 31, 2019 as well as MannKind’s other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Company Contact:

818-661-5000
[email protected]

SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM, BEEMW), the leading provider of innovative sustainable technology for electric vehicle (EV) charging, outdoor media and energy security, today announced that its CEO, Desmond Wheatley, will be presenting at the 13th annual LD Micro Main Event investor conference on Tuesday, December 15 at 12:20 p.m. EST.

“The LD Micro Main Event investor conference provides a high-quality opportunity to describe the value and growth opportunities that Beam continues to create,” said Beam Global CEO, Desmond Wheatley. “I’m looking forward to updating the investment community on our progress and our plans. By all accounts 2021 is set to be an excellent year for the electrification of transportation and I believe that it will be an excellent year for Beam Global.”

Register here:


ve.mysequire.com/

The Main Event will feature a new and unique format, with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts.

“The time has finally come to do something different in the virtual conference world. Let’s see if we can pull off something that can be enjoyed by both executives and investors alike,” stated Chris Lahiji, Founder of LD, now a wholly owned subsidiary of SRAX, Inc.

The Main Event will take place on December 14th and 15th, exclusively on the Sequire Virtual Events platform.

View Beam
Global’s
profile


here


.

Profiles powered

by LD Micro

About
Beam Global

Beam Global is a Cleantech leader that produces innovative, sustainable technology for electric vehicle (EV) charging, outdoor media, and energy security, without the construction, disruption, risks and costs of grid-tied solutions. Products include the patented EV ARC™ and Solar Tree® lines with BeamTrak™ patented solar tracking, and ARC Technology™ energy storage, along with EV charging, outdoor media and disaster preparedness packages.

The company develops, patents, designs, engineers and manufactures unique and advanced renewably energized products that save customers time and money, help the environment, empower communities and keep people moving. Based in San Diego, the company produces Made in America products. Beam Global is listed on Nasdaq under the symbols BEEM and BEEMW (formerly Envision Solar, EVSI, EVSIW). For more information visit https://BeamForAll.com/, LinkedIn, YouTube and Twitter.

About LD Micro/SEQUIRE

LD Micro began in 2006 with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. For more information, please visit ldmicro.com.

The upcoming Main Event will be highlighting a new format that will benefit both executives and the investors tuning in from all over the globe.

In September 2020, LD Micro. Inc. was acquired by SRAX, Inc., a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit srax.com and mysequire.com.

Forward-Looking Statements

This Beam Global Press Release may contain forward-looking statements. All statements in this Press Release other than statements of historical facts are forward-looking statements. Forward-looking statements are generally accompanied by terms or phrases such as “estimate,” “project,” “predict,” “believe,” “expect,” “anticipate,” “target,” “plan,” “intend,” “seek,” “goal,” “will,” “should,” “may,” or other words and similar expressions that convey the uncertainty of future events or results.

Investor Relations:

Kathy McDermott
[email protected]
+1 858-799-4583

Media Contact:

The Bulleit Group
[email protected]
+1 415-742-1894

Source: Beam Global via LD Micro

– The plinabulin + pegfilgrastim combination reduces the incidence of
profound neutropenia
(ANC < 0.1 x 10E9 cells/L) by
53 % vs. pegfilgrastim alone

– The plinabulin + pegfilgrastim combination reduces the odds of having
febrile neutropenia by 41% vs. pegfilgrastim alone, based on reduction of profound neutropenia

– Posters
p
resented at
the
2020 San Antonio Breast Cancer Symposium

NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) — BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the new data from its Phase 3 PROTECTIVE-2 Study 106 demonstrating that plinabulin in combination with pegfilgrastim offers greater protection against chemotherapy-induced neutropenia (CIN) than the standard of care, pegfilgrastim alone. The study not only met the primary and key secondary objectives, as previously disclosed on Nov. 16, 2020, but also demonstrated that the combination was 53% more effective than pegfilgrastim alone in reducing the incidence of profound neutropenia (absolute neutrophil count or ANC < 0.1 x 10E9 cells/L), 21.6% vs. 46.4%, respectively, p=0.0001, in patients with breast cancer undergoing chemotherapy with TAC (docetaxel, doxorubicin, and cyclophosphamide). Profound neutropenia (PN) is a well-known risk factor to increase the rates of infection, febrile neutropenia (FN), and hospitalization among patients undergoing chemotherapy. Of clinical importance, the combination has shown to reduce the odds of having FN by 41% in comparison to pegfilgrastim, based on reduction of profound neutropenia.

“It is clinically meaningful to reduce FN risk by 41% in the combination, compared to pegfilgrastim alone, which is the only major breakthrough advancement in CIN prevention in the last 30 years. The CIN protection from plinabulin added to pegfilgrastim, particularly in the first week of chemotherapy when 75% of CIN-related complications occur before the effect of pegfilgrastim kicks-in in Week 2, fills the treatment gap in current standard of care,” said Douglas Blayney, M.D., Professor of Medicine at Stanford Medical School, and global PI for the plinabulin CIN studies. “The combination of plinabulin with pegfilgrastim represents a major advancement in offering protection against CIN, with the potential to reduce FN risk, in the care of cancer patients.”

The data were presented via a poster at the 2020 San Antonio Breast Cancer Symposium (SABCS): “Superior and Clinically Meaningful Protection Against Profound Neutropenia with the Plinabulin/Pegfilgrastim (Plin/Peg) Combination versus Peg In Breast Cancer Patients Receiving TAC Chemotherapy.” Profound neutropenia, an exploratory endpoint representing the most severe form of CIN, is associated with significant risk to patients and may require antibacterial or antifungal prophylaxis [Flowers JCO 2013]. It is attributed to both febrile neutropenia (48%) and infection (50%) [Bodey Cancer 1978]. In BeyondSpring’s PROTECTIVE-2 studies, patients with profound neutropenia had close to nine times the risk of FN compared to patients with no profound neutropenia. The new data presented at SABCS included:

• 53% reduction in
  profound neutropenia
  i
  ncidence
  : combination (21.6%) vs. pegfilgrastim alone (46.4%), p=0.0001;
• 50% reduction in m
  ean duration of
  profound neutropenia
  : combination (0.3 day) vs. pegfilgrastim alone (0.6 day), p= 0.0004;
• The combination reduces the odds of FN by 41% vs. pegfilgrastim alone, due to its ability to reduce patients’ exposure to profound neutropenia.

This trial is a global, multicenter, randomized, double-blinded study in patients with breast cancer undergoing myelosuppressive chemotherapy with TAC (docetaxel at 75 mg/m2, doxorubicin at 50 mg/m2, and cyclophosphamide at 500 mg/m2) for the evaluation of protection against CIN, comparing plinabulin (40 mg) in combination with pegfilgrastim (6 mg) in 111 patients to pegfilgrastim alone (6 mg) in 110 patients. On Day 1, they received TAC and plinabulin or placebo, and on Day 2, they received pegfilgrastim. Topline data from the Protective-2 Phase 3 trial were reported on November 16, 2020 highlighting that the study met its primary endpoint as well as key secondary endpoints.

“It is well recognized that CIN is directly related to chemotherapy’s ability to kill rapidly dividing cells. Unfortunately, fast dividing neutrophils in the bone marrow are adversely affected regardless of the chemotherapy type. As a result, we believe these outcomes are universally applicable to any chemotherapy, and are independent of cancer types,” added Gordon Schooley, Ph.D., BeyondSpring’s Chief Regulatory Officer. “As both the U.S. FDA and China NMPA recently awarded BeyondSpring’s Plinabulin CIN program with Breakthrough Therapy Designation status based on the interim phase 3 data of PROTECTIVE-2, and the Company now completing the PROTECTIVE-2 trial with positive and consistent results to the interim, we are well on track to submit our NDA for CIN in Q1 2021. The improved CIN prevention benefit of the Plinabulin/G-CSF combination would have the potential for CIN prevention of the myelosuppressive effects of different chemotherapeutic agents in millions of patients with multiple tumor types.”

Ramon Mohanlal, M.D., Ph.D., BeyondSpring’s Chief Medical Officer and Executive Vice President, Research and Development concluded, “Plinabulin represents a new treatment paradigm for CIN prevention, an area wherein G-CSF has established efficacy, but with short-comings due to its delayed onset of action, next day dosing requirement, bone pain induction, and platelet count reduction. Plinabulin has a fast onset mechanism of action, without causing relevant bone pain or thrombocytopenia, and can be given on the same day as chemotherapy. Plinabulin added to G-CSF offers superior prevention of CIN, and has the potential to avoid life-threatening infections and to improve short-term and long-term survival. Plinabulin’s anticancer activity from its immune-enhancing mechanism of action, together with its CIN preventive effects, has the potential to become a universal add-on to anti-cancer treatments in general.”

The above data are available on BeyondSpring’s website in the Posters section.

About Plinabulin

Plinabulin, BeyondSpring’s lead asset, is a differentiated immune and stem cell modulator. Plinabulin is currently in late-stage clinical development to increase overall survival in cancer patients, as well as to alleviate chemotherapy-induced neutropenia (CIN). The durable anticancer benefits of Plinabulin have been associated with its effect as a potent antigen-presenting cell (APC) inducer (through dendritic cell maturation) and T-cell activation (Chem and Cell Reports, 2019). Plinabulin’s CIN data highlight the ability to boost the number of hematopoietic stem / progenitor cells (HSPCs), or lineage-/cKit+/Sca1+ (LSK) cells in mice. Effects on HSPCs could explain the ability of Plinabulin not only to treat CIN, but also to reduce chemotherapy-induced thrombocytopenia and increase circulating CD34+ cells in patients.

About CIN

Patients receiving chemotherapy typically develop chemotherapy-induced neutropenia (CIN), a severe side effect that increases the risk of infection with fever (also called febrile neutropenia, or “FN”), which necessitates ER/hospital visits. The updated National Comprehensive Cancer Network (NCCN) guidelines expanded the use of prophylactic G-CSFs, such as pegfilgrastim, to include not only high- risk patients (chemo FN rate>20%), but also intermediate-risk patients (FN rate between 10-20%) to avoid hospital/ER visits during the COVID-19 pandemic. The revision of the NCCN guidelines effectively doubles the addressable market of patients who may benefit from treatment with plinabulin, if approved, to approximately 440,000 cancer patients in the U.S. annually. Plinabulin is designed to provide protection against the occurrence of CIN and its clinical consequences in week 1, for early onset of action after chemotherapy. CIN is the primary dose-limiting toxicity in cancer patients who receive chemotherapy treatment.

About BeyondSpring 
BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring’s lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. The U.S. FDA granted Breakthrough Therapy designation to plinabulin for concurrent administration with myelosuppressive chemotherapeutic regimens in patients with non-myeloid malignancies for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to plinabulin, including three immuno-oncology assets and a drug discovery platform using the protein degradation pathway, which is being developed in a subsidiary company, Seed Therapeutics, Inc. The Company also has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company’s future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring’s most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Media Contacts

Investor Contact:

Ashley R. Robinson
LifeSci Advisors, LLC
+1 617-430-7577
[email protected] 

Media Contact:

Darren Opland, Ph.D.
LifeSci Communications
+1 646-627-8387
[email protected]